Reacción a "A vaccine to prevent pancreatic cancer in high-risk individuals is safe and induces long-lasting immune responses in a phase 1 trial"

This is undoubtedly a high-quality, relevant article on a tumor with a very poor prognosis, one that opens up a new treatment option for these KRAS-mutated patients. The study is fully consistent with various previous studies targeting the same molecular target and tumor—which is why a clinical trial could be conducted, as such trials always require prior supporting evidence—but it is also applicable to other tumors.

Preventive use would be conceptually possible outside of familial cases, but it would be difficult to apply in most cases (which are sporadic).

The main limitation is that this is an initial trial primarily aimed at establishing safety and surrogate evidence of efficacy (induced responses). Efficacy remains to be demonstrated, although it may only be achieved—based on these safety findings—after combining the vaccine with other immunotherapies.